2. Academic Validation
  3. CPT2 gene mutations resulting in lethal neonatal or severe infantile carnitine palmitoyltransferase II deficiency

CPT2 gene mutations resulting in lethal neonatal or severe infantile carnitine palmitoyltransferase II deficiency

  • Mol Genet Metab. 2008 Aug;94(4):422-427. doi: 10.1016/j.ymgme.2008.05.002.
Paul J Isackson 1,  Michael J Bennett 2,  Uta Lichter-Konecki 3,  Mary Willis 4,  William L Nyhan 4,  V Reid Sutton 5,  Ingrid Tein 6,  Georgirene D Vladutiu 1
Affiliations

Affiliations

  • 1 Department of Pediatrics, School of Medicine & Biomedical Sciences, State University of New York at Buffalo, SUNY at Buffalo, 100 High Street, Buffalo, NY 14203, USA.
  • 2 Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine and Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • 3 Department of Pediatrics, The George Washington University Medical Center & Children's National Medical Center, Washington, DC, USA.
  • 4 Department of Pediatrics, University of California San Diego, La Jolla, CA, USA.
  • 5 Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
  • 6 Division of Neurology, The Research Institute, The Hospital for Sick Children & The University of Toronto, Toronto, Ont., Canada.
PMID: 18550408 DOI: 10.1016/j.ymgme.2008.05.002
Abstract

Three distinct clinical manifestations of carnitine palmitoyltransferase II (CPT II) deficiency have been defined including a mild adult onset myopathy, a severe infantile disorder and a lethal neonatal form. In this study we have examined the genomic DNA of five patients, 3 with the lethal neonatal form and 2 with the severe infantile form of the disease and identified two disease-causing mutations in the CPT2 gene for each patient, three of which are novel. In addition, based on currently available structural, biochemical and clinical data, we have classified all 64 known disease-causing mutations into groups with different predicted phenotypes depending on their CPT2 allelic counterparts.

Figures